RXDX
Undervalued by 3.3% based on the discounted cash flow analysis.
Market cap | $9.56 Billion |
---|---|
Enterprise Value | $9.48 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $-3.49 |
Beta | -0.49 |
Outstanding Shares | 47,461,230 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -57.28 |
---|---|
PEG | -207.6 |
Price to Sales | - |
Price to Book Ratio | 14.28 |
Enterprise Value to Revenue | 2371.91 |
Enterprise Value to EBIT | -58.19 |
Enterprise Value to Net Income | -64 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0.04 |
No data
No data
Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis...